ATP binding cassette subfamily C member 9Genealiases: ABC37 · ATFB12 · CANTU · CMD1O · IDMYS · SUR2
Q-omics provides the consensus-scored ABCC9 profile across patient tissues and cancer cell-line models. ABCC9 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ABCC9 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, ABCC9 RNA expression shows 23,391 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, LUAD, and LSCC as cancer lineages where ABCC9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABCC9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABCC9 survival associations across molecular data types. ABCC9 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABCC9 RNA expression–survival associations across cancer types. High ABCC9 expression shows unfavorable associations in BLCA, UVM, KIRP, LUSC, ACC and THCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ABCC9 RNA expression.
This table summarizes ABCC9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ABCC9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABCC9 shows lower tumor expression in LUAD, KICH, THCA, LUSC, LIHC and BLCA. The LUAD box plot shows higher ABCC9 RNA expression in normal versus tumor tissue (log2 FC = −1.182, t-test p < 0.001).
This table shows molecular features associated with ABCC9 in patient tissues and cancer cell lines. In patient samples, ABCC9 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABCC9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
